Alzheimer’s Blood Tests Take Center Stage on Social Media, but Misleading Claims Persist, Study Finds

A new study from the University of Sydney has revealed that social media platforms are playing a significant role in shaping public perceptions of Alzheimer’s disease blood tests, often promoting claims that diverge sharply from current clinical recommendations. The research, published in the Journal of the American Geriatrics Society, is the first of its kind to systematically analyze how these emerging diagnostic tools are being presented to the public across major social media platforms. The findings come at a pivotal moment, as Alzheimer’s blood tests have recently become available in Australia since July, generating substantial public interest and, according to the researchers, considerable misinformation.

The research team analyzed 188 posts shared between March 2014 and May 2025 on Facebook, Instagram, and TikTok that discussed Alzheimer’s blood tests. These posts originated from accounts with a combined audience exceeding 114 million followers, illustrating the enormous reach that health-related content can achieve on social platforms. The study employed a cross-sectional content analysis methodology, allowing researchers to categorize posts according to their claims, the presence or absence of supporting evidence, and whether they aligned with established clinical guidance regarding appropriate use of the tests.

Among the most concerning findings was that more than a third of the analyzed posts suggested the blood tests could be used to screen healthy individuals who show no symptoms of cognitive decline. This recommendation directly conflicts with current clinical guidelines, which advise against routine testing of asymptomatic people. The blood tests are designed to support diagnosis of Alzheimer’s disease specifically in individuals already experiencing cognitive symptoms, not as general screening tools for the broader population. Despite this, social media content frequently blurred the line between diagnostic use and widespread screening.

Dr. Jenna Smith, the lead author of the study from the University of Sydney’s School of Public Health and the Sydney Health Literacy Lab, emphasized the gap between social media enthusiasm and scientific evidence. She noted that social media is presenting exciting claims about what these new blood tests might be able to do, but that excitement can outpace the evidence. According to Dr. Smith, people increasingly turn to social media for health information, and when content omits important context about who these tests are for, their limitations, and potential downsides, there is a real risk that individuals may develop unrealistic expectations or seek testing that is not clinically recommended for them.

The analysis revealed that 59 percent of posts promoted the blood tests as useful for earlier or improved diagnosis of Alzheimer’s disease. While this claim has some basis in clinical practice, many posts failed to mention that a comprehensive clinical assessment remains essential to any diagnosis, or that the tests are only recommended for people experiencing symptoms of cognitive decline. This omission is significant because blood biomarkers for Alzheimer’s disease, while increasingly accurate, are intended as one component of a broader diagnostic process that includes cognitive evaluation, clinical history, and in some cases imaging or cerebrospinal fluid analysis.

Perhaps most striking was the finding regarding evidence quality and financial incentives. Only 36 percent of the posts included any evidence supporting their claims, and fewer than one quarter of those cited a specific study. Even more concerning, accounts with explicit financial interests were more than three times as likely to promote testing for people without symptoms compared to accounts without such interests. This correlation suggests that commercial motivations may be driving some of the most misleading content, potentially encouraging healthy individuals to pursue testing that offers no proven benefit and carries real risks of harm.

The researchers highlighted several potential harms associated with testing asymptomatic individuals that were rarely mentioned in the social media posts discussing this use case. These harms include overdiagnosis, false positive results, and the broader psychological and social impacts that an Alzheimer’s diagnosis can have on individuals and their families. Dr. Smith explained that dementia is one of the most feared health conditions among adults, and understandably, people want answers and may be drawn to new tests that appear to offer certainty or early detection. However, for people without symptoms, there is currently no evidence that screening provides any benefit.

A positive test result in an asymptomatic person may create significant anxiety and uncertainty, particularly given that there is no cure for Alzheimer’s disease and that guidance on how these new tests should be used is still evolving. Furthermore, people with no symptoms could potentially be diagnosed with Alzheimer’s disease based on biomarker evidence but never go on to develop dementia that actually impacts their daily life. This phenomenon of biomarker-positive but clinically asymptomatic individuals underscores the complexity of interpreting these tests outside of a proper clinical context and highlights why current recommendations advise against routine screening of healthy populations.

The study’s authors are calling for several responses to address these issues. They emphasize the need for clear, evidence-based information to help the public understand who may benefit from testing and what the results can and cannot tell them. Dr. Smith noted that these tests may play an important role in supporting diagnosis for some people experiencing cognitive symptoms, but they should be interpreted with appropriate clinical oversight. She stressed the importance of consumers receiving balanced information rather than relying on social media alone, and recommended that posts should always include advice to speak with a health professional before undertaking any Alzheimer’s blood testing.

Looking forward, the researchers say clinicians should also be aware of how social media may shape public perceptions of Alzheimer’s blood tests, as patients increasingly arrive at appointments with preconceived notions formed by online content. They are calling for improved regulatory enforcement to address misleading health claims on social platforms, alongside the development of resources to support meaningful conversations between patients and healthcare providers about the benefits, limitations, and uncertainties surrounding Alzheimer’s blood testing. As these diagnostic tools become more widely available and public interest continues to grow, ensuring that accurate, balanced information reaches consumers will be essential to preventing harm while preserving legitimate access to valuable diagnostic advances for those who truly need them.

Subject of Research: Social media misinformation about Alzheimer's disease blood tests and their appropriate clinical use

Article Title: Social media spreading misleading claims about Alzheimer’s blood tests, study finds

Article References: Social media spreading misleading claims about Alzheimer’s blood tests, study finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Alzheimer's disease, blood tests, social media, health misinformation, dementia, clinical recommendations, Social, media, spreading, misleading, claims, Alzheimer